Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15055812 | 0.91 | EPHX2 (0.38) | UTS2REPHX2KDM4EGAAPKM | |
| Trifluoroacetic Acid SCHEMBL15055426 | 0.88 | KDM4E (0.41) | UTS2REPHX2KDM4EGAAPKM | |
| SCHEMBL15055366 | 0.87 | EPHX2 (0.40) | UTS2REPHX2KDM4EGAAPKM | |
| SCHEMBL15080050 | 0.86 | KDM4E (0.45) | UTS2REPHX2KDM4EGAAPKM | |
| SCHEMBL15056049 | 0.85 | EPHX2 (0.46) | UTS2REPHX2KDM4EGAAPKM | |
| SCHEMBL15055272 | 0.82 | EPHX2 (0.40) | EPHX2 | |
| SCHEMBL15055922 | 0.82 | KDM4E (0.38) | EPHX2KDM4EGAAPKMPTGS2 | |
| SCHEMBL19288224 | 0.81 | ALDH1A1 (0.34) | UTS2REPHX2KDM4EGAAPKM | |
| SCHEMBL15059166 | 0.80 | PFKFB3 (0.52) | EPHX2KDM4EPTGS2PTGS1 | |
| SCHEMBL15055040 | 0.79 | PFKFB3 (0.41) | UTS2REPHX2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2016-08-04 | — | — | US | claimed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | claimed |
| EP-2794009-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | Kancera AB (SE) | 2014-10-29 | — | — | EP | claimed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | claimed |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2018-06-19 | — | — | US | disclosed |
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | disclosed |
| US-9718809-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2016-08-04 | — | — | US | disclosed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | disclosed |
| EP-2794009-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | Kancera AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | UTS2R 1462/4885EPHX2 2619/4885KDM4E 2715/4885 |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | UTS2R 1459/4885EPHX2 2645/4885KDM4E 2807/4885 |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | NFKBIA, IL6, LITAF | UTS2R 1459/4885EPHX2 2645/4885KDM4E 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.